27th October 2017, Volume 130 Number 1464

Scott Metcalfe, Sanji Gunasekara, Kate Baddock, Lesley Clarke, for the New Zealand Medical Association

As the term of the new coalition government begins, the New Zealand Medical Association (NZMA) urges all parties to invest in the health of New Zealanders. Last month’s release of…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Summary

Spending on health is a positive investment in individuals’ and family/whānau health, wellbeing and productivity, and saves money elsewhere in our economy. The NZMA’s ‘Health as an Investment’ position statement supports an investment approach to health that takes the long-term view, consistent across the sector and sectors. Addressing the social determinants of health is crucial, as health equity both improves economic performance and relieves pressure on the health system itself. This demands inter-sectoral and whole-of-government approaches.

Author Information

Scott Metcalfe, Board Member; Sanji Gunasekara, Manager Policy and Stakeholder Relations;
Kate Baddock, Chair; Lesley Clarke, Chief Executive, New Zealand Medical Association, Wellington.

Acknowledgements

Liz Springford, Frank Frizelle, Sharon Cuzens, Harvey White, David Galler, Marise Stuart,
Stephen Child,Ruth Spearing, Elizabeth Berryman, Buzz Burrell, Jan White, Magnus Cheesman,
Michael Chen-Xu, Catherine Hallagan, Deborah Lambie.

Correspondence

Kate Baddock, New Zealand Medical Association, PO Box 156, Wellington.

Correspondence Email

nzma@nzma.org.nz

Competing Interests

SM is employed by PHARMAC; the views expressed do not necessarily represent those of PHARMAC.

References

  1. New Zealand Medical Association. NZMA Position Statement on Health as an Investment. Wellington: NZMA, 2017. http://www.nzma.org.nz/__data/assets/pdf_file/0003/77277/Health-as-an-investment_FINAL.pdf 
  2. World Bank. Investing in health: World Development Report 1993. New York: The World Bank & Oxford University Press, 1993. http://documents.worldbank.org/curated/en/468831468340807129/World-developmentreport-1993-investing-in-health 
  3. Allin S, Mossialos E, McKee M, Holland W. The Wanless report and decision-making in public health. J Public Health (Oxf). 2005; 27(2):133–4. jpubhealth.oxfordjournals.org/content/27/2/133.full.pdf 
  4. Suhrcke M, McKee M, Stuckler D, et al. The contribution of health to the economy in the European Union. Public Health. 2006; 120(11):994–1001. http://users.ox.ac.uk/~chri3110/Details/Public%20Health%20article%202006.pdf 
  5. Reeves A, Basu S, McKee M, et al. Does investment in the health sector promote or inhibit economic growth? Global Health. 2013; 9:43. http://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603-9-43 
  6. New Zealand Health Strategy 2016. Wellington: Ministry of Health, 2016. http://www.health.govt.nz/publication/new-zealand-health-strategy-2016 
  7. Wanless D. Securing good health for the whole population. London: HM Treasury, 2004 http://webarchive.nationalarchives.gov.uk/20130129110402/http://www.hm-treasury.gov.uk/consult_wanless04_final.htm 
  8. Treasury. Guide to Social Cost Benefit Analysis. Wellington: NZ Treasury, 2015. http://www.treasury.govt.nz/publications/guidance/planning/costbenefitanalysis/guide 
  9. Gauld R. Ahead of its time? Reflecting on New Zealand’s Pharmac following its 20th anniversary. Pharmacoeconomics. 2014;32(10):937-42. http://link.springer.com/article/10.1007%2Fs40273-014-0178-2; with correction by: Metcalfe S et al. Clarification from PHARMAC: PHARMAC Takes No Particular Distributive Approach (Utilitarian or Otherwise). Pharmacoeconomics 2014; 32:1031–1033. http://link.springer.com/article/10.1007/s40273-014-0208-0/fulltext.html 
  10. Gluckman P. The role of evidence in policy formation and implementation: a report from the Prime Minister’s Chief Science Advisor. Wellington: Office of the Prime Minister’s Chief Science Advisor, 2013. http://www.pmcsa.org.nz/wp-content/uploads/The-role-of-evidence-in-policy-formation-and-implementation-report.pdf
  11. Gluckman P. Enhancing evidence-informed policy making: a report by the Prime Minister’s Chief Science Advisor. Wellington: Office of the Prime Minister’s Chief Science Advisor, 2017. http://www.pmcsa.org.nz/wp-content/uploads/17-07-07-Enhancing-evidence-informed-policy-making.pdf
  12. World Medical Association, WMA Resolution on Improved Investment in Public Health. WMA, 2009. http://www.wma.net/en/30publications/10policies/h13/ 
  13. Gauld R. Questions about New Zealand’s health system in 2013, its 75th anniversary year. N Z Med J. 2013; 126(1380):68–74. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2013/vol-126-no-1380/view-gauld 
  14. Keene L, Bagshaw P, Nicholls MG, Rosenberg B, Frampton CM, Powell I. Funding New Zealand’s public healthcare system: time for an honest appraisal and public debate. N Z Med J. 2016; 129(1435):10–20. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2016/vol-129-no-1435-27-may-2016/6891 
  15. The Treasury’s CBAx tool. Wellington: NZ Treasury, 2016. http://www.treasury.govt.nz/publications/guidance/planning/costbenefitanalysis/cbax 
  16. Lipscomb J, Weinstein MC, Torrance GW. Time preference. in: Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, Daniels N, Weinstein MC. Identifying and valuing outcomes. in: Gold MR, Siegel JE, Russell LB, Weinstein MC (eds.). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. pp 214–46.
  17. Milne R. Valuing prevention: discounting health benefits and costs in New Zealand. N Z Med J. 2005; 118(1214). http://www.nzma.org.nz/__data/assets/pdf_file/0004/17941/Vol-118-No-1214-06-May-2005.pdf
  18. Metcalfe S, Brougham M, Moodie P, Grocott R. PHARMAC responds to Richard Milne on discounting health benefits and costs. N Z Med J. 2005; 118(1219). http://www.pharmac.govt.nz/assets/nzmj-2005-07-29-pharmac-responds-to-richard-milne-on-discounting.pdf 
  19. Milne R. Richard Milne responds to PHARMAC on discounting future health benefits and costs. N Z Med J. 2005; 118(1220):U1620. http://www.nzma.org.nz/__data/assets/pdf_file/0003/17931/Vol-118-No-1220-12-August-2005.pdf
  20. Grocott R, Metcalfe S. PHARMAC’s updated guidelines for cost-effectiveness analyses, with new discount rate. N Z Med J. 2007; 120(1258):U2641. http://www.pharmac.govt.nz/assets/nzmj-2007-07-20-pharmacs-updated-guidelines-for-cost-effectiveness-analyses-with-new-discount-rate.pdf
  21. PHARMAC. Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Version 2.2. Wellington: PHARMAC; 2015. http://www.pharmac.govt.nz/assets/pfpa-2-2.pdf 
  22. Guide to Social Cost Benefit Analysis. Wellington: NZ Treasury, 2015. http://www.treasury.govt.nz/publications/guidance/planning/costbenefitanalysis/guide pp 33–8.
  23. PHARMAC. Factors for Consideration. Wellington: PHARMAC, 2016. http://www.pharmac.govt.nz/medicines/how-medicines-arefunded/factors-for-consideration/supporting-information/
  24. Singer P, McKie J, Kuhse H, Richardson J. Double jeopardy and the use of QALYs in health care allocation. J Med Ethics. 1995; 21:144–50. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1376689/pdf/jmedeth00296-0016.pdf 
  25. New Zealand Medical Association. NZMA Position Statement on Health Equity. Wellington: NZMA, 2011. http://www.nzma.org.nz/__data/assets/pdf_file/0016/1456/Health-equity-2011.pdf 
  26. The World Bank. Equity and development: World Development Report 2006. New York: The World Bank & Oxford University Press, 2006. http://siteresources.worldbank.org/INTWDR2006/Resources/477383-1127230817535/082136412X.pdf 
  27. Williams D, Garbutt B, Peters J. Core Public Health Functions for New Zealand. N Z Med J. 2015; 128(1418):16–26. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2015/vo-128-no-1418-24-july-2015/6592 
  28. Wilson N. Commentary on ‘Core public health functions for New Zealand’ [Editorial]. N Z Med J. 2015; 128(1418):7–10. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2015/vo-128-no-1418-24-july-2015/6589 
  29. Masters R, Anwar E, Collins B, Cookson R, Capewell S. Return on investment of public health interventions: a systematic review J Epidemiol Comm Health 2017; 71:827–834. http://jech.bmj.com/content/jech/71/8/827.full.pdf 
  30. OECD. Universal health coverage and health outcomes: final report for the G7 Health Ministerial meeting, Kobe, Japan, 11–12 September 2016. Paris: OECD, 2016. http://www.oecd.org/els/health-systems/Universal-Health-Coverage-and-Health-Outcomes-OECD-G7-Health-Ministerial-2016.pdf 
  31. Marmot M, Friel S, Bell R, Houweling TA, Taylor S. Commission on Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. Lancet. 2008; 372(9650):1661–9. http://www.sciencedirect.com/science/article/pii/S0140673608616906 

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe